Michell G.

Michell G. has extensive experience in the oncology and rare disease sectors, holding leadership roles in various pharmaceutical companies since 2009. Notably, Michell G. served as Division Manager for Clovis Oncology, leading a team to commercialize Rucaparib, an FDA Designated Breakthrough Therapy. Other significant positions include Regional Sales Director for GSK, where a team facilitated the launch of Tafinlar/Mekinist, and Regional Business Director for Corcept Therapeutics, focusing on GYN oncology. At UroGen Pharma, Michell G. successfully launched JELMYTO, the first non-surgical treatment for low-grade upper tract urothelial cancer. Additional accomplishments include receiving the 2024 RBD Rookie of the Year Award at Agios Pharmaceuticals and optimizing commercial operations at Seagen.